Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7379
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    95,270.92
    -20.38 (-0.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6844
    +0.0001 (+0.01%)
     

Lucid Diagnostics to Have a Productive Year, Says Cantor Fitzgerald

By Sam Boughedda

Investing.com -- Lucid Diagnostics Inc (NASDAQ:LUCD) shares rose 5% on Tuesday after Cantor Fitzgerald analyst Ross Osborn reiterated an overweight rating and $12 price target.

Osborn said the company "will have a productive year with the launch in new geographic areas supported by a sales team that is expected to double in size."

Regarding the company's reported fourth quarter results, Osborn said Lucid's revenue came in slightly below its and FactSet consensus expectations, but they believe the variability comes with the early-stage nature of the company.

"Testing volumes grew an impressive 50% QoQ and 200% YoY as the company's initial commercialization efforts are tracking well," stated the analyst.

ADVERTISEMENT

The analyst concluded that they "encourage investors to acquire LUCD's shares at what we believe represents an attractive valuation."

Related Articles

Lucid Diagnostics to Have a Productive Year, Says Cantor Fitzgerald

lululemon (LULU) Stock Jumps 7% on Q4 Beat and Raise, $1B Buyback

Lululemon forecasts strong 2022 on consistent demand for athletic wear